<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588586</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0866</org_study_id>
    <secondary_id>1U01AI118536-01</secondary_id>
    <nct_id>NCT02588586</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Antiretroviral Activity of 3BNC117</brief_title>
  <official_title>An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying&#xD;
      rebound of viral load during a brief treatment interruption of standard ART, and its safety&#xD;
      during a brief analytical interruption of antiretroviral therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a Phase II, open label study to evaluate the safety, antiretroviral&#xD;
      activity and pharmacokinetics of four infusions of 3BNC117 in HIV-infected individuals on&#xD;
      combination ART and during a brief analytical treatment interruption (ATI).&#xD;
&#xD;
      Study participants will be administered four intravenous infusions of 3BNC117, administered&#xD;
      at 30 mg/kg on day 0, week 12, week 24 and week 27. Antiretroviral therapy will be&#xD;
      discontinued 2 days after the third 3BNC117 infusion (week 24), until week 36.&#xD;
&#xD;
      The ART regimen will be resumed at week 36 or sooner if plasma HIV-1 RNA level is ≥ 200&#xD;
      copies/ml, CD4+ T cell count drops &lt; 350 cells/microliter, and results are confirmed upon&#xD;
      repeat measurement during the next weekly scheduled visit. If plasma HIV-1 RNA level is ≥&#xD;
      1,000 copies/ml, the participant will be asked to return for a repeat measurement prior to&#xD;
      the next scheduled visit, and ART will be resumed if results are confirmed. ART will also be&#xD;
      resumed early if the participant becomes pregnant or if otherwise clinically indicated. If&#xD;
      ART is resumed before week 27, the fourth 3BNC117 infusion will not be administered.&#xD;
&#xD;
      Participants will be followed weekly during the analytical treatment interruption phase for&#xD;
      safety assessments and for monitoring plasma HIV-1 RNA levels. CD4+ T cell counts will be&#xD;
      monitored every 2 weeks during the analytical treatment interruption phase.&#xD;
&#xD;
      Participants may remain off antiretroviral therapy after week 36, with weekly viral load&#xD;
      monitoring, if viral rebound does not occur by week 36.&#xD;
&#xD;
      All participants will be followed for a total of 60 weeks from enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Viral Rebound at 12 Weeks After Interruption of Antiretroviral Therapy</measure>
    <time_frame>36 weeks</time_frame>
    <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of 3BNC117 at the Time of Viral Rebound, Measured in Micrograms Per ml</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum level of 3BNC117 at the time of viral rebound, measured in micrograms per ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Viral Rebound After Interruption of Antiretroviral Therapy</measure>
    <time_frame>36 weeks</time_frame>
    <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>60 weeks</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>3BNC117 + ART Interruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117</intervention_name>
    <description>3BNC117 infusions</description>
    <arm_group_label>3BNC117 + ART Interruption</arm_group_label>
    <other_name>3BNC117 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiretroviral Treatment Interruption</intervention_name>
    <description>Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
    <arm_group_label>3BNC117 + ART Interruption</arm_group_label>
    <other_name>Treatment Interruption</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained and signed.&#xD;
&#xD;
          -  Males and females, age 18 to 65.&#xD;
&#xD;
          -  HIV-1 infection confirmed by two independent methods.&#xD;
&#xD;
          -  Plasma HIV-1 RNA &lt; 50 copies/ml for at least 12 months while on combination ART and &lt;&#xD;
             20 copies/ml at the screening visit. [Note: One or two viral blips of &lt; 200 copies/mL&#xD;
             prior to enrollment are permitted if preceded and followed by test results showing VL&#xD;
             less than or equal to 50 copies/ml on the same ARV regimen.]&#xD;
&#xD;
          -  CD4 cell count &gt; 500 cells/microliter. CD4 cell count nadir &gt; 200 cells/microliter.&#xD;
&#xD;
          -  If sexually active male or female, and participating in sexual activity that could&#xD;
             lead to pregnancy, agrees to use an effective method of contraception throughout the&#xD;
             study period. Participants should also agree to use a male or female condom while off&#xD;
             ART.&#xD;
&#xD;
          -  Female study participants of reproductive potential are defined as pre-menopausal&#xD;
             women who have not had a sterilization procedure (e.g. hysterectomy, bilateral&#xD;
             oophorectomy, tubal ligation or salpingectomy). Women are considered menopausal if&#xD;
             they have not had a menses for at least 12 months and have a FSH of greater than 40&#xD;
             IU/L or if FSH testing is not available, they have had amenorrhea for 24 consecutive&#xD;
             months.&#xD;
&#xD;
          -  Acceptable forms of contraception must include one of the following: condoms (male or&#xD;
             female) with or without a spermicidal agent, diaphragm or cervical cap with&#xD;
             spermicide, IUD, or hormone-based contraceptive.&#xD;
&#xD;
          -  If on an NNRTI-based regimen willing to a switch for 4 weeks to a dolutegravir-based&#xD;
             regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of AIDS-defining illness within 1 year prior to enrollment.&#xD;
&#xD;
          -  Have a history of resistance to two or more antiretroviral drug classes.&#xD;
&#xD;
          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other&#xD;
             medications considered significant by the trial physician within the last 6 months.&#xD;
&#xD;
          -  Chronic hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Participant report, or chart history, of significant coronary artery disease,&#xD;
             myocardial infarction, percutaneous coronary intervention with placement of cardiac&#xD;
             stents.&#xD;
&#xD;
          -  Participant report, or chart history, of diabetes type 1 or 2 and/or current use of&#xD;
             insulin or oral hypoglycemic medications.&#xD;
&#xD;
          -  Uncontrolled hypertension, as defined by a systolic blood pressure &gt; 180 and/or&#xD;
             diastolic blood pressure &gt; 120, in the presence or absence of anti-hypertensive&#xD;
             medications.&#xD;
&#xD;
          -  Total cholesterol level &gt; 240 mg/dl or LDL level &gt; 190 mg/dl at screen.&#xD;
&#xD;
          -  Known family history of myocardial infarction or stroke in a first-degree relative&#xD;
             aged &lt; 60 years.&#xD;
&#xD;
          -  Any other clinically significant acute or chronic medical condition, such as&#xD;
             autoimmune diseases, that in the opinion of the investigator would preclude&#xD;
             participation.&#xD;
&#xD;
          -  Current cigarette use in excess of 1 pack per day;&#xD;
&#xD;
          -  Laboratory abnormalities in the parameters listed below:&#xD;
&#xD;
          -  Absolute neutrophil count less than or equal to 1,000 cells/microliter&#xD;
&#xD;
          -  Hemoglobin less than or equal to 10 g/dL&#xD;
&#xD;
          -  Platelet count less than or equal to 125,000 cells/microliter&#xD;
&#xD;
          -  ALT greater than or equal to 2.0 x ULN&#xD;
&#xD;
          -  AST greater than or equal to 2.0 x ULN&#xD;
&#xD;
          -  Total bilirubin greater than or equal to 1.5 ULN&#xD;
&#xD;
          -  Creatinine greater than or equal to 1.1 x ULN&#xD;
&#xD;
          -  Coagulation parameters greater than or equal to 1.5 x ULN.&#xD;
&#xD;
          -  Current antiretroviral regimen includes maraviroc or enfuvirtide.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Any vaccination within 14 days prior to 3BNC117 administration.&#xD;
&#xD;
          -  Receipt of monoclonal antibody therapy of any kind in the past.&#xD;
&#xD;
          -  History of severe reaction to drug infusions or history of severe allergic reactions.&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within past 12 weeks, or expected participation during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>May 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2021</results_first_posted>
  <disposition_first_submitted>April 16, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 30, 2019</disposition_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Marina Caskey, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Investigation</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>3BNC117</keyword>
  <keyword>Broadly neutralizing antibody</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02588586/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02588586/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No pre-assignment phase</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3BNC117 + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults living with HIV and on suppressive antiretroviral therapy</population>
      <group_list>
        <group group_id="B1">
          <title>3BNC117 + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="26" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Viral Rebound at 12 Weeks After Interruption of Antiretroviral Therapy</title>
        <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3BNC117 + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Viral Rebound at 12 Weeks After Interruption of Antiretroviral Therapy</title>
          <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of 3BNC117 at the Time of Viral Rebound, Measured in Micrograms Per ml</title>
        <description>Serum level of 3BNC117 at the time of viral rebound, measured in micrograms per ml</description>
        <time_frame>12 weeks</time_frame>
        <population>3BNC117 serum levels</population>
        <group_list>
          <group group_id="O1">
            <title>3BNC117 + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of 3BNC117 at the Time of Viral Rebound, Measured in Micrograms Per ml</title>
          <description>Serum level of 3BNC117 at the time of viral rebound, measured in micrograms per ml</description>
          <population>3BNC117 serum levels</population>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.87" spread="27.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Viral Rebound After Interruption of Antiretroviral Therapy</title>
        <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3BNC117 + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Viral Rebound After Interruption of Antiretroviral Therapy</title>
          <description>Viral rebound is defined as confirmed plasma HIV-1 RNA level &gt; 200 copies/ml in two separate occasions</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
        <time_frame>60 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3BNC117 + ART Interruption</title>
            <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3BNC117 + ART Interruption</title>
          <description>Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.&#xD;
3BNC117: 3BNC117 infusions&#xD;
Antiretroviral Treatment Interruption: Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychotic episode</sub_title>
                <description>Hospitalization for an acute psychotic episode 6 days after the second 3BNC117 infusion. Deemed not related to study drug but to underlying bipolar disorder.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Malaise or fatigue</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was an exploratory open label study with a small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Marina Caskey, Professor of Clinical Investigation</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>2123277396</phone>
      <email>mcaskey@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

